dr. nielsen on the challenges of using ki67 as a tool in breast cancer
Published 11 years ago • 311 plays • Length 1:01Download video MP4
Download video MP3
Similar videos
-
0:49
dr. nielsen on the clinical utility of ki67 in breast cancer
-
1:19
dr. nielsen on the pros and cons of the ki67 assay in breast cancer
-
1:29
dr. nielsen discusses using a ki67 assay in breast cancer
-
1:52
dr. ellis discusses ki67 as a treatment monitoring biomarker
-
10:05
ki-67 shows proven clinical utility as a predictive clincal biomarkers for breast cancer
-
2:25
comment: lumina results show that women with low levels of the ki67 biomarker can avoid outcomes...
-
6:09
ki-67 index after neoadjuvant et as a prognostic biomarker for hr /her2- early breast cancer
-
2:07
lumina results: women with low levels of the ki67 biomarker can avoid outcomes related to rt
-
2:47
the value of mipi and ki-67 in mantle cell lymphoma
-
1:32
dr. nicholas robert on ma.17r trial for patients with early-stage breast cancer
-
1:36
dr. verma on her2 testing and the utility of ki67
-
1:09
priya rastogi, md, provides details on the subgroup of patients with ki-67 status from monarche
-
0:29
5 symptoms of breast cancer | warning signs of breast cancer | dr niharika garach
-
4:04
stanford oncologist, douglas blayney, md, discusses breast cancer
-
2:07
dr. nielsen discusses the pam50 assay
-
0:50
dr. ellis discusses the cell-proliferation marker ki67
-
1:12
the use of ki-67, a proliferation marker, for guiding treatment decisions in breast cancer patients
-
0:50
how to tell if you have breast cancer #shorts
-
1:21
the use of the ki-67 in deciding which patients with hr breast cancer can safely avoid chemotherapy